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-Dystrobrevin (DB), a cytoplasmic component of the
dystrophin–glycoprotein complex, is found throughout
the sarcolemma of muscle cells. Mice lacking 
 
 
 
DB exhibit
muscular dystrophy, defects in maturation of neuromuscular
junctions (NMJs) and, as shown here, abnormal myotendi-
nous junctions (MTJs). In normal muscle, alternative splicing
produces two main 
 
 
 
DB isoforms, 
 
 
 
DB1 and 
 
 
 
DB2, with
 
common NH
 
2
 
-terminal but distinct COOH-terminal domains.
 
 
 
DB1, whose COOH-terminal extension can be tyrosine
phosphorylated, is concentrated at the NMJs and MTJs.
 
 
 
DB2, which is not tyrosine phosphorylated, is the pre-
dominant isoform in extrajunctional regions, and is also
 
 
present at NMJs and MTJs. Transgenic expression of either
 
isoform in 
 
 
 
DB
 
 
 
/
 
 
 
 mice prevented muscle ﬁber degeneration;
however, only 
 
 
 
DB1 completely corrected defects at the
NMJs (abnormal acetylcholine receptor patterning, rapid
turnover, and low density) and MTJs (shortened junctional
folds). Site-directed mutagenesis revealed that the effective-
ness of 
 
 
 
DB1 in stabilizing the NMJ depends in part on its
ability to serve as a tyrosine kinase substrate. Thus, 
 
 
 
DB1
phosphorylation may be a key regulatory point for synaptic
remodeling. More generally, 
 
 
 
DB may play multiple roles
in muscle by means of differential distribution of isoforms
with distinct signaling or structural properties.
 
Introduction
 
The dystrophin–glycoprotein complex (DGC),* which is
found throughout the sarcolemma of skeletal muscle cells,
forms a multimolecular, transmembrane link between the
intracellular cytoskeleton and the extracellular basal lamina
(Ervasti and Campbell, 1993). Constituents of the DGC
include dystrophin, utrophin, dystroglycans (
 
 
 
 and 
 
 
 
),
sarcoglycans (
 
 
 
, 
 
 
 
, 
 
 
 
, 
 
 
 
,
 
 
 
and 
 
 
 
), syntrophins (
 
 
 
1, 
 
 
 
1, and
 
 
 
2), dystrobrevins (DBs; 
 
 
 
 and 
 
 
 
), and sarcospan (Ervasti et
al., 1990; Yoshida and Ozawa, 1990; for review see Blake et
al., 2002). Interest in the DGC stemmed originally from the
finding that mutations in genes encoding numerous DGC
components cause muscular dystrophy: loss of dystrophin
results in Duchenne muscular dystrophy; deficiencies in four
of the sarcoglycans have been linked to limb-girdle muscular
dystrophies; and mutations in laminin 
 
 
 
 2, the main extra-
cellular ligand for the DGC, lead to congenital muscular
dystrophy (Cohn and Campbell, 2000; Blake et al., 2002).
In addition to its role in myofiber integrity, the DGC is
also important in formation or maintenance of two specialized
domains on the muscle fiber surface: neuromuscular junctions
(NMJs), at which motor axons innervate muscle fibers, and
myotendinous junctions (MTJs), at which muscle fibers
form load-bearing attachments to tendons. The DGC is
dispensable for initial steps in postsynaptic differentiation,
but contributes importantly to the maturation and stabilization
of the postsynaptic membrane. For example, myotubes lacking
dystroglycan, utrophin, 
 
 
 
1-syntrophin, or 
 
 
 
DB have alter-
ations in the density and patterning of acetylcholine receptors
(AChRs) embedded within the postsynaptic membrane
(Deconinck et al., 1997a; Grady et al., 1997a, 2000; Adams
et al., 2000; Jacobson et al., 2001; Akaaboune et al., 2002).
Roles of the DGC have been less extensively studied at the
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MTJ, but several DGC components are concentrated in this
region (e.g., dystrophin, utrophin, syntrophin, sarcospan,
and nNOS [Chen et al., 1990; Byers et al., 1991; Khurana
et al., 1991; Chang et al., 1996; Crosbie et al., 1999]), and
MTJs are structurally abnormal in mice lacking dystrophin
or both dystrophin and utrophin (Ridge et al., 1994; De-
coninck et al., 1997b).
Little is known about how the DGC plays these disparate
roles, but one important factor is that its composition varies
among cell types (Straub et al., 1999; Loh et al., 2000;
Moukhles and Carbonetto, 2001) and, for muscle cells at
least, from site to site within a single cell. In muscle fibers,
dystrophin is present throughout the sarcolemma, whereas its
autosomal homologue, utrophin, is confined to the NMJ and
MTJ (Khurana et al., 1991; Ohlendieck et al., 1991). Like-
wise, each of the three syntrophins has a distinct sarcolemmal
distribution (Kramarcy and Sealock, 2000). Here, we focus
on another DGC component, 
 
 
 
DB, to address the issue of
how isoform diversity contributes to functional diversity.
 
 
 
DB is found throughout the sarcolemma in vertebrate skel-
etal muscle, where it binds dystrophin, utrophin, and syntro-
phin (Carr et al., 1989; Wagner et al., 1993; Peters et al.,
1997b, 1998; Sadoulet-Puccio et al., 1997). A homologue,
 
 
 
DB, has been described but is expressed at low levels if at all
in skeletal muscle (Peters et al., 1997a; Blake et al., 1998).
Previously, we showed that 
 
 
 
DB
 
 
 
/
 
 
 
 knockout mice exhibit
both muscular defects (muscular dystrophy) and abnormal
NMJs (Grady et al., 1999, 2000; Akaaboune et al., 2002). In
addition, we show here that 
 
 
 
DB
 
 
 
/
 
 
 
 mice have malformed
MTJs. Thus, 
 
 
 
DB influences DGC function at three distinct
locations within the muscle cell.
Several isoforms of 
 
 
 
DB are generated by alternative splic-
ing, of which three, 
 
 
 
DB1–3, have been detected in skeletal
muscle (Blake et al., 1996; Sadoulet-Puccio et al., 1996;
Enigk and Maimone, 1999; Newey et al., 2001a) They are
identical over most of their length (551 aa) but have distinct
COOH termini (Fig. 1 A). The 188 aa COOH terminus of
 
 
 
DB1 is a substrate for tyrosine kinases in vivo (Wagner et
al., 1993; Balasubramanian et al., 1998), whereas common
sequences and the short (16 aa) COOH terminus of 
 
 
 
DB2
do not appear to undergo phosphorylation. 
 
 
 
DB3 lacks the
syntrophin- and dystrophin-binding sites present in the
other isoforms and has not been studied in detail. Although
both 
 
 
 
DB1 and 
 
 
 
DB2 are concentrated at the postsynaptic
membrane, their detailed localization differs within the
junction; furthermore, only 
 
 
 
DB2 is present at high levels
in extrasynaptic regions (Peters et al., 1998; Newey et al.,
2001a). Based on these differences, we hypothesized that
 
 
 
DB1 and 
 
 
 
DB2 might have distinct functions. In addi-
tion, based on evidence that tyrosine phosphorylation regu-
lates the plasticity of neuron–neuron synapses (Ali and
Salter, 2001), we wanted to test the theory that tyrosine
phosphorylation of 
 
 
 
DB1 affects neuromuscular maturation
or structure.
To directly assess these ideas, we expressed 
 
 
 
DB1 or
 
 
 
DB2 in 
 
 
 
DB
 
 
 
/
 
 
 
 mice and analyzed the ability of each iso-
form to “rescue” the dystrophic, synaptic, and myotendi-
nous phenotypes. We show that either 
 
 
 
DB1 or 
 
 
 
DB2 is
able to maintain muscle stability but that 
 
 
 
DB1 is signifi-
cantly better than 
 
 
 
DB2 in preventing synaptic and myo-
tendinous defects. We also used sited-directed mutagenesis
to show that the enhanced efficacy of 
 
 
 
DB1 depends in part
on its tyrosine phosphorylation.
 
Results
 
Generation of transgenic mice
 
We generated transgenic mice in which regulatory elements
from the muscle creatine kinase gene were linked to cDNAs
Figure 1. Generation of transgenic mice. (A) Structure of  DB, 
showing the two main isoforms expressed in muscle and the regions 
recognized by anti- DB antibodies (pan-DB, DB1, and DB2). Also 
shown are binding regions for syntrophin (SYN; hatched area) and 
dystrophin (DYS; black area), sequences unique to  DB2 (gray hatched 
area), and sites in  DB1 that undergo tyrosine phosphorylation in 
vivo (P). (B) Immunoblot of whole muscle extracts stained with a 
pan-DB antibody. Equal amounts (50  g) of protein were loaded for 
each genotype (wt; wild-type). Molecular weight markers are shown 
in kD. (C) Immunostaining of skeletal muscle from the four genotypes 
with a pan-DB antibody.  DB is expressed in  95% of muscle fibers 
in both transgenic lines.T
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encoding 
 
 
 
DB1 or 
 
 
 
DB2. Transgenic mice were bred to
 
 
 
DB
 
 
 
/
 
 
 
 mice (Grady et al., 1999, 2000). We studied two
transgenic lines that expressed 
 
 
 
DB1 (12 and 14) and three
that expressed 
 
 
 
DB2 (11A, 11B, and 28). In the text and
figures, the designations tgDB1 and tgDB2 refer to lines 12
and 28, respectively. However, the main results were con-
firmed with the other lines (see Materials and methods).
Immunoblotting with antibodies that recognize all 
 
 
 
DB
isoforms showed that levels of transgene expression were
similar in the tgDB1 and tgDB2 lines (Fig. 1 B). Levels of
recombinant 
 
 
 
DB2 in 
 
 
 
DB
 
 
 
/
 
 
 
,tgDB2 were similar to levels
of endogenous 
 
 
 
DB2 in control mice, whereas levels of re-
combinant 
 
 
 
DB1 in 
 
 
 
DB
 
 
 
/
 
 
 
,tgDB1 muscle were signifi-
cantly higher then levels of endogenous 
 
 
 
DB1 but similar to
levels of total 
 
 
 
DB in controls (Fig. 1 B). Immunohis-
tochemical analysis showed that 
 
 
 
DB1 and 
 
 
 
DB2 were
present in 
 
 
 
95% of all muscle fibers in 
 
 
 
DB
 
 
 
/
 
 
 
,tgDB1 and
 
 
 
DB
 
 
 
/
 
 
 
,tgDB2 mice, respectively (Fig. 1 C). In both lines,
the transgene was expressed in all skeletal muscles tested, in-
cluding tibialis anterior, sternomastoid, and diaphragm, and
there were no detectable differences among fibers that corre-
lated with fiber type (unpublished data).
 
Muscular dystrophy
 
 
 
DB
 
 /  mice exhibit a mild muscular dystrophy character-
ized by degenerating myofibers, infiltrating monocytes,
and centrally nucleated regenerating myotubes (Fig. 2)
(Grady et al., 1999). To test whether  DB1 and  DB2 dif-
fer in their ability to maintain muscular integrity, we examined
the diaphragm, quadriceps, soleus, sternomastoid, and tibialis
anterior muscles of  DB
 / ,tgDB1 and  DB
 / ,tgDB2
mice. The diaphragm provided a particularly stringent test
Figure 2.  DB1 and  DB2 both prevent muscle fiber degeneration 
in  DB
 /  mice. Hematoxylin and eosin–stained sections of 
skeletal muscle from wild-type,  DB
 / ,  DB
 / ,tgDB1, and 
 DB
 / ,tgDB2 mice. Regenerated muscle fibers are centrally 
nucleated, indicating that some of the initial cohort of fibers had 
degenerated. No histological evidence for muscle fiber degeneration 
or regeneration was seen in either  DB
 /  transgenic line. Insets 
show high power images.
Figure 3. Localization of  DB isoforms in  DB
 /  and mdx mice 
expressing  DB1 and/or  DB2. Sections of skeletal muscle stained 
with antibodies that recognize  DB1,  DB2, or both (pan-DB). 
Sections were counterstained with rBTX to identify synaptic sites, 
which are indicated by arrowheads. (A) In wild-type muscle, both 
 DB1 and 2 are enriched at the synapse, whereas  DB2 is the 
predominant extrasynaptic isoform. Both isoforms are absent from 
 DB
 /  muscle, although weak synaptic reactivity of unknown 
molecular identity is seen using the DB2 antibody (Grady et al., 2000). 
In  DB
 / ,tgDB1 and  DB
 / ,tgDB2 muscle, transgene-encoded 
 DB is present throughout the sarcolemma and enriched at synaptic 
sites. For  DB2, this pattern is similar to that seen in control muscle, 
but the extrasynaptic abundance of transgenic  DB1 is greater 
than in controls. In  DB
 /  muscle expressing both  DB1 and 2 
(DB
 / ,tgDB1/DB2), extrasynaptic  DB1 is retained and  DB2 
decreases. (B) In mice lacking dystrophin (mdx), sarcolemmal 
expression of both isoforms is reduced. Likewise, only low levels of 
extrasynaptic  DB are present in mdx mice expressing recombinant 
 DB1 (mdx,DB
 / ,tgDB1).T
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because it is the most severely affected muscle in several
models of muscular dystrophy, including  DB
 /  mice
(Stedman et al., 1991; Grady et al., 1997b, 1999; Duclos
et al., 1998). Rescue by both transgenes was dramatic. No
degenerating fibers, regenerating (centrally nucleated) fi-
bers, or infiltration by monocytes were detected in any
muscles of either  DB
 / ,tgDB1 or  DB
 / ,tgDB2 mice
(Fig. 2 and unpublished data). This was true in mice rang-
ing in age from 1–7 mo, in muscles with predominantly
fast (type IIB and II) fibers (tibialis anterior, quadriceps,
diaphragm, and sternomastoid), and in muscles with pre-
dominantly slow (type I and IIA) fibers (soleus). Thus, ei-
Figure 4.  DB1 is better able than  DB2 to restore normal AChR density and distribution to  DB
 /  mice. (A) Longitudinal sections of 
wild-type,  DB
 / ,  DB
 / ,tgDB1, and  DB
 / ,tgDB2 muscle stained with rBTX. In wildtype synapses, AChRs form multiple branches with 
smooth borders. Within branches, AChRs are evenly distributed or faintly striated. In  DB
 /  synapses, AChRs are patchily distributed with 
fragmented branch borders and radiating spicules. In  DB
 / ,tgDB1 synapses, AChR pattern is essentially normal. In the majority of  DB
 / ,tgDB2 
synapses, AChRs are patchily distributed, but spicules of AChRs at branch borders are shorter than those of mutants. (B) Synaptic density (  SE) 
of AChRs in each of the four genotypes as assessed by their mean fluorescence intensity after incubation with a saturating dose of rBTX. AChR 
density in  DB
 /  synapses (n   49) is  30% of wild-type (n   18). At  DB
 / ,tgDB1 synapses (n   49), AChR density recovers to control 
levels, whereas in  DB
 / ,tgDB2 synapses (n   19) density remains intermediate between wild-type and  DB
 / . (C) High power images of 
branches from synapses such as those shown in A to highlight differences in AChR patterning. Spicules are indicated by arrowheads.T
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ther  DB1 or  DB2 alone is capable of maintaining mus-
cle fiber integrity.
Synaptic localization of  DB isoforms
We immunostained muscles with antibodies specific for
 DB1 and  DB2 (Fig. 1 A). Consistent with previous re-
ports, both isoforms are present at higher levels at synaptic
sites (marked with rhodamine  -bungarotoxin [rBTX],
which binds specifically and quasiirreversibly to AChRs)
than in extrasynaptic regions of the sarcolemma (Peters et al.,
1998; Grady et al., 2000). Likewise, recombinant  DB1 and
 DB2 were concentrated at synaptic sites in  DB
 / ,tgDB1
and   DB
 / ,tgDB2 mice, respectively (Fig. 3 A). For
 DB2, the endogenous and recombinant proteins were dis-
tributed similarly. However, whereas endogenous  DB1
was barely detectable extrasynaptically, recombinant  DB1
was abundant extrasynaptically (Fig. 3 A). Thus, selective lo-
calization of  DB1 to the NMJ in wild-type muscle cannot
be explained solely by its primary sequence.
The abundance of extrasynaptic  DB1 in  DB
 / ,tgDB1
muscle might result from its higher than normal levels (Fig.
1 B). An alternative, however, is that restriction of  DB1 to
synaptic sites requires the presence of  DB2. For example,
 DB2 might have a higher affinity than  DB1 for extrasyn-
aptic-binding sites and thereby displace  DB1 from such
sites. To test this hypothesis, we generated doubly transgenic
 DB
 /  mice that expressed  DB1 and  DB2 at similar
levels. In  DB
 / ,tgDB1/DB2 mice,  DB2 was clearly
present extrasynaptically, but its presence failed to reduce ex-
trasynaptic levels of  DB1 (Fig. 3 A). Indeed, levels of
membrane-associated   DB2 immunoreactivity were de-
creased when  DB1 was present, suggesting that  DB2 did
not bind selectively to extrasynaptic sites.
We also exploited the presence of extrasynaptic  DB1 to
test whether  DB1 depends on the DGC for its localization
to the sarcolemma. Levels of endogenous  DB, primarily
 DB2, are greatly reduced in extrasynaptic regions of dys-
trophin-deficient (mdx) mice (Grady et al., 1997b). How-
ever, there is evidence for dystrophin-independent associa-
tions of  DB with the sarcolemma (Crawford et al., 2000),
and these associations might be sufficient to tether  DB1 to
the membrane. We found that levels of extrasynaptic  DB1
remained low in mdx, DB
   ,tgDB1 mice despite the
overexpression of recombinant  DB1 (Fig. 3 B). Con-
sistent with this result, there was no attenuation of dys-
trophic symptoms in mdx, DB
   ,tgDB1 compared with
mdx, DB
    mice (unpublished data). Thus unique se-
quences in  DB1 neither mediate a DGC-independent as-
sociation with the membrane nor attenuate dystrophy in the
absence of dystrophin.
AChR distribution and density
Normal adult mouse NMJs are pretzel shaped with
an AChR-rich postsynaptic membrane underlying each
branch of the nerve terminal.  DB deficiency does not
greatly affect the overall topology of the NMJ but does af-
fect the arrangement of its AChRs in three ways (Fig. 4)
(Grady et al., 2000; Akaaboune et al., 2002). First, AChRs
smoothly outline each branch in controls, whereas branch
borders in mutants are fragmented with long finger-like
spicules that radiate beyond the terminal’s edge. Second,
AChRs in control NMJs are enriched along the crests of
the junctional folds that invaginate the postsynaptic mem-
brane, leading to a striated appearance within each branch.
In  DB
 /  synapses, in contrast, the distinction between
the crests and folds is blurred (shown ultrastructurally in
Grady et al., 2000) with receptors forming small, irregu-
larly spaced aggregates or clumps. Finally, the density of
AChRs is reduced by  70% at  DB
 /  synapses com-
pared with controls.
Expression of  DB1 in mice prevented all three of these
defects: AChR distribution and density were indistinguish-
able from normal at  95% of synaptic sites examined (Fig.
4). Thus,  DB1 alone can support postsynaptic maturation.
In contrast, in  DB
 / ,tgDB2 mice examined at 4–6 wk
of age the postsynaptic membrane remained abnormal at
 90% of synaptic sites: AChRs formed small aggregates
comparable to those seen at  DB
 /  synapses rather than
the linear striations characteristic of normal muscle. On the
other hand, most  DB
 / ,tgDB2 postsynaptic sites were
distinguishable from those in mice lacking all  DB, in that
spicules radiating from the edge of the AChR-rich region
were either absent or short and AChR density was slightly
but significantly greater than in mutants (Fig. 4, B and C).
Thus,  DB2 supports normal postsynaptic maturation to a
lesser degree than  DB1.
Figure 5.  DB1 is better able than 
 DB2 to restore normal AChR turnover 
to  DB
 /  mice. Turnover of AChRs as 
assessed by the change in fluorescence 
intensity in rBTX-labeled synapses over 
a 3-d period. (A) Grayscale images used 
to calculate t1/2. (B) AChRs in wild-type 
synapses had an average t1/2 of  10.5 d 
(  SE, n   20), whereas those of  DB
 /  
synapses (n   56) were  2.5 d. AChR t1/2 
in  DB
 / ,tgDB1 synapses (n   45) was 
similar to that of control mice, whereas 
t1/2 of  DB
 / ,tgDB2 synapses (n   33) 
was intermediate between control and 
 DB
 / .T
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The difference between  DB
 / ,tgDB1 and  DB
 / ,
tgDB2 synapses was also evident in 3–6-mo-old animals.
However, the percentage of normal-appearing synapses in
 DB
 / ,tgDB2 increased to  50% at 6 mo of age. This
age-related increase suggests that the continued presence of
even the relatively ineffective  DB2 can eventually normal-
ize the structure of initially abnormal synapses. Moreover, it
raises the possibility that differences between  DB1 and
 DB2 are quantitative rather than qualitative. In this regard,
it is important to note that levels of transgene expression
were similar in  DB
 / ,tgDB1 and  DB
 / , DB2 mice
(Fig. 1 B). Moreover, studies of transfected muscle fibers,
described below, provide independent evidence that  DB1-
specific sequences play a distinct role.
AChR turnover
AChRs migrate and turn over faster at  DB
 /  synapses
than in controls, supporting the idea that  DB acts in
part by tethering AChRs to the postsynaptic cytoskeleton
(Akaaboune et al., 2002). Because little is known about the
molecular mechanisms that regulate AChR turnover, we
quantitated rBTX fluorescence in vivo (see Materials and
methods) to ask whether  DB1 and  DB2 had different ef-
fects on this process. Adult sternomastoid muscles were la-
beled with a single nonsaturating dose of rBTX, and individ-
ual synapses were imaged. 3 d later, the same synapses were
located and imaged again to assess changes in fluorescence
intensity. In wild-type mice,  20% of the labeled receptors
were lost from the cell surface after 3 d. This degree of loss
indicates a t1/2 of  10.5 d, similar to previous reports
(Akaaboune et al., 1999, 2002). In  DB
 /  mice, nearly
60% of AChRs were lost over a similar time, indicating a t1/2
of  2.5 d (Fig. 5). AChR stability in  DB
 / ,tgDB1 mice
did not differ significantly from that of controls (t1/2    9 d),
whereas the t1/2 of AChRs in  DB
 / ,tgDB2 mice was in-
termediate between controls and mutants (t1/2    5.5 d).
Thus, consistent with the results on AChR distribution and
density,  DB1 alone can support normal AChR turnover,
whereas  DB2 is only partially effective.
Synaptic localization of  1-syntrophin 
and nitric oxide synthase
To further investigate mechanisms that might account for the
greater ability of  DB1 than  DB2 to support synaptic matu-
ration, we studied the distribution of two proteins whose con-
centration at synaptic sites requires  DB:  1-syntrophin and
neuronal nitric oxide synthase (nNOS). Levels of both are re-
duced synaptically and extrasynaptically in  DB
 /  mice
(Grady et al., 2000). Moreover,  1-syntrophin mutants have
synaptic defects similar to those seen in  DB
 /  mice (Adams
et al., 2000), and studies in vitro have implicated nNOS as a
modulator of AChR clustering (Jones and Werle, 2000).
In  DB
 / ,tgDB1 muscle, synaptic levels of  1-syntro-
phin and nNOS were similar to those in controls (Fig. 6). In
contrast, levels of  1-syntrophin and nNOS remained low
in many synapses of  DB
 / ,tgDB2 mice. Interestingly,
when viewed en face,  DB
 / ,tgDB2 synapses with the low-
est levels of  1-syntrophin also had the most abnormal
AChR distribution (unpublished data). Thus, although ei-
ther  DB isoform can recruit  1-syntrophin and nNOS to
the NMJ, the increased efficacy of  DB1 over  DB2 in
maintaining synaptic architecture may reflect in part its in-
creased recruiting ability.
Role of tyrosine phosphorylation in  DB1 function
The COOH-terminal domain of  DB1 is tyrosine phos-
phorylated in vivo (Balasubramanian et al., 1998), raising
the possibility that tyrosine phosphorylation is important
for its synaptic function. To test this idea, we fused GFP to
the NH2 terminus of  DB1 (GFP-DB1) or to a mutant
form of  DB1 in which the three major phosphorylated ty-
rosine residues (aa 698, 706, and 723 [Balasubramanian et
al., 1998]) had been changed to phenylalanine by site-
directed mutagenesis (GFP-DB1-P3
 ). Expression of these
constructs in heterologous cells showed that only the GFP-
DB1 fusion protein underwent tyrosine phosphorylation
(Fig. 7 A). Thus, the addition of GFP to  DB1 did not
preclude its phosphorylation, whereas the mutation of its
three tyrosine residues did. The two constructs were intro-
Figure 6. Localization of DGC-associated proteins in  DB mutant 
and transgenic mice. Sections of skeletal muscle were stained with 
antibodies to nNOS or  1-syntrophin ( 1-syn). In wild-type muscle, 
nNOS and  1-syntrophin are present throughout the sarcolemma 
with enrichment at the synaptic sites (arrowheads). In  DB
 /  muscle, 
membrane levels of both proteins were reduced. Expression of 
 DB1 restored normal levels of both proteins to  DB
 /  muscle. In 
 DB
 / ,tgDB2 muscle, levels of nNOS and  1-syntrophin remained 
lower than normal at many sites.T
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duced into tibialis anterior muscles of 2-wk-old  DB
 / 
mice by electroporation. Muscles were removed 10–14 d
later, transfected fibers were identified by GFP fluores-
cence, and their postsynaptic membranes were analyzed
(Fig. 7, B and C).
GFP-DB1 and GFP-DB1-P3
  were expressed at equal
levels based on fluorescence intensity and were concentrated
at synaptic sites to a similar extent (Fig. 7 B), yet they af-
fected AChR distribution in different ways. Expression of
GFP-DB1 in  DB
 /  myofibers resulted in significant res-
toration of postsynaptic structure at most synaptic sites, and
AChR distribution was qualitatively normal at a subset of
NMJs (Fig. 7, D–F). Expression of GFP-DB1-P3
  also re-
stored AChR distribution to some extent, but the recovery
was significantly less than that seen with GFP-DB1 (p  
0.0001 by Chi-square test), and no synaptic sites appeared
normal (Fig. 7, D–F). The variability of “rescue” seen
among transfected fibers was greater than that seen in
 DB
 /  transgenic mice, possibly because GFP interfered
with  DB function or because electroporation led to vari-
able protein levels. Nonetheless, these results indicate a role
for tyrosine phosphorylation in the function of  DB1.
Figure 7. Impaired restoration of 
postsynaptic structure in  DB
 /  
muscle by  DB1 that lacks tyrosine 
phosphorylation sites. (A) Immunoblot of 
HEK293 cells transfected with no DNA, 
GFP-DB1, or GFP-DB1-P3
  expression 
constructs, lysed, and immunopurified 
with anti-GFP antibodies. Cells 
were treated with ( ) or without ( ) 
pervanadate before lysis to inhibit tyrosine 
phosphatases. Protein was identified 
with either an anti- DB antibody (DB) or 
an antiphosphotyrosine antibody (P-tyr). 
Only GFP-DB1 from pervanadate-
treated cells was tyrosine phosphorylated. 
(B) Fiber bundles from  DB
 /  skeletal 
muscles that had been electroporated in 
vivo with GFP-DB1 or GFP-DB1-P3
  2 wk 
earlier. After dissection, muscles were 
stained with rBTX. Myofibers expressing 
either fusion protein demonstrate similar 
fluorescence along the entire sarcolemma 
with concentrations at synaptic sites. 
(C) High power images of synapses from 
transfected muscle fibers showing that 
both GFP-DB1 and GFP-DB1-P3
  are 
highly concentrated at synaptic sites. 
(D) Muscle fibers stained with rBTX. 
Expression of GFP-DB1 in  DB
 /  muscle 
leads to a qualitatively normal AChR 
pattern with synaptic branches having 
linear striations and relatively smooth 
borders. GFP-DB1-P3
  has less ability 
to restore normal AChR distribution in 
 DB
 /  muscle with many synapses 
having patchy clusters of AChRs and 
fragmented branch borders. (E) High 
power images of branches from 
synapses such as those shown in D to 
highlight differences in AChR patterning. 
(F) Comparison of AChR distribution in 
wild-type fibers (87 synapses),  DB
 /  
fibers (90 synapses), and in fibers 
electroporated with GFP-DB1 (118 
synapses) or GFP-DB1-P3
  (161 
synapses). Categories 1 and 4
were synapses typical of wild-type and 
 DB
 /  muscle, respectively; categories 
2 and 3 were intermediate. Numbers 
represent percentages of total synapses 
examined. Approximately 70% of syn-
apses in fibers expressing GFP-DB1 fell 
into category 1 or 2 with  1% in category 
4. In contrast, over 70% of synapses in
fibers expressing GFP-DB1-P3
  fell into 
category 3 or 4 with none in category 1.T
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Interestingly, the qualitative differences between  DB
 / 
fibers transfected with GFP-DB1 and GFP-DB1-P3
  paral-
leled the differences described above between  DB
 / ,
tgDB1 and  DB
 / ,tgDB2 fibers. Expression of  DB1 ei-
ther transgenically or by transfection resulted in postsynap-
tic sites with sharp, spicule-free borders and striated instead
of granular interiors. In contrast, although expression of ei-
ther  DB2 or GFP-DB1-P3
  in  DB
 /  muscle usually
led to restoration of sharp (spicule-poor) borders, interiors
remained granular (Fig. 4 B compared with Fig. 7 D).
These parallels suggest that the enhanced ability of  DB1
over  DB2 to support synaptic structure depends on its ty-
rosine phosphorylation.
The MTJ
In initial studies, we found that both  DB1 and  DB2 were
enriched at the MTJ in wild-type mice (Fig. 8). We there-
fore asked whether  DB is required for the integrity of the
MTJ. We used EM to address this issue. The muscle mem-
brane at the MTJ is invaginated to form folds that run paral-
lel to the myofiber’s long axis (Fig. 9 A). These folds, which
are deeper than those of the NMJ, create an interdigitation
with the collagen fibrils of the tendon. Folds were also
present at mutant MTJs but were significantly shorter than
those in controls (Fig. 9, difference between control and
 DB
 /  p   0.0001 by ANOVA). Thus,  DB is important
for maintaining normal MTJ architecture.
Based on these results, we asked whether  DB1 and
 DB2 differed in their ability to maintain MTJ structure. In
 DB
 / ,tgDB1 mice, the depth of the folds was not signifi-
cantly different from wild-type (Fig. 9 B; p   0.25), whereas
folds in  DB
 / ,tgDB2 mice were significantly shorter than
those of wild-type or  DB
 / ,tgDB1 animals (p   0.0001).
Thus,  DB1 was significantly more effective than  DB2 in
maintaining the integrity of both MTJs and NMJs. Because
we could not identify transfected fibers in the electron mi-
Figure 8. Localization of  DB isoforms 
at the MTJ. Sections of skeletal muscle 
were stained with antibodies to  DB1, 
 DB2, or both (pan-DB). (A) In wild-type 
muscle, both  DB1 and 2 were enriched 
at the MTJ (arrowheads). (B) In  DB
 /  
muscle, both forms were absent. In both 
 DB
 / ,tgDB1 and DB
 / ,tgDB2 muscle, 
transgene-encoded  DB was restored to 
the MTJ.
Figure 9. MTJ structure is abnormal 
in  DB
 /  mice and restored more 
completely by  DB1 than by  DB2. 
(A) Electron micrographs of MTJs from 
wild-type,  DB
 / ,  DB
 / ,tgDB1, and 
 DB
 / ,tgDB2 mice. Normal MTJs are 
characterized by multiple folds with 
long slender projections of muscle (M) 
interdigitating with the collagen fibrils 
of the tendon (T). In  DB
 /  MTJs, folds 
are shallower with blunted muscle 
projections. In  DB
 / ,tgDB1 mice, 
the MTJs appear similar to wild-type, 
whereas in  DB
 / ,tgDB2 mice the MTJs 
retain many features of  DB
 /  MTJs. 
(B) Measurements of MTJ folds revealed 
that folds in  DB
 /  MTJs (n   437 folds) 
are half the size of normal folds (n   203). 
Folds in  DB
 / ,tgDB1 MTJs (n   245) 
were similar to controls, whereas those 
of  DB
 / ,tgDB2 MTJs (n   230) were 
intermediate between control and  DB
 / .T
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croscope, we were unable to test whether  DB1 phosphory-
lation plays a role in MTJ maintenance.
Discussion
The DGC plays at least three distinct roles in muscle: main-
taining sarcolemmal integrity and stabilizing the structure of
both the NMJ and the MTJ. Genetic studies in mice have
shown that loss of some DGC components affects one func-
tion and not others. For example, absence of dystrophin or
of  -sarcoglycan results in muscular dystrophy with little
impact upon the NMJ (Hack et al., 1998; Grady et al.,
2000; Akaaboune et al., 2002). Conversely, mice lacking
utrophin or  1-syntrophin have abnormal synapses with no
detectable dystrophy (Deconinck et al., 1997a; Grady et al.,
1997a; Kameya et al., 1999; Adams et al., 2000). In con-
trast,  DB is critical for all three DGC functions. In this pa-
per, we show that  DB’s disparate effects are explained in
part through alternative splicing of the  DB transcript and
selective localization of the two main muscle isoforms,
 DB1 and  DB2.
Muscular dystrophy and  DB
In normal muscle,  DB2 is the predominant extrasynaptic
isoform, suggesting that it plays the primary role in helping
the DGC maintain muscle viability. Although we found
that expression of  DB2 alone in  DB
 /  mice prevented
muscle fiber degeneration,  DB1 was equally capable. These
findings show that the unique COOH terminus of  DB2 is
not required for its effect upon the membrane and suggest
that shared sequences suffice. Shared domains include sites
that mediate binding of  DB to dystrophin and syntrophin.
Also included are two EF hand domains and a zinc finger re-
gion that can potentially mediate other protein–protein in-
teractions (for review see Enigk and Maimone, 2001).
Ligands for these sites are unknown but may include novel
 DB-binding proteins identified recently in yeast two-
hybrid screens (Benson et al., 2001; Mizuno et al., 2001;
Newey et al., 2001b). Thus, it is likely that both  DB1 and
2 can maintain myofiber integrity by attracting similar bind-
ing partners to the DGC.
On the other hand, loss of  DB1-specific functions at the
MTJ may contribute to muscle pathology.  DB1 is better
able than  DB2 to maintain the integrity of the MTJ. The
MTJ is the major site of force transmission from muscle fi-
bers to the skeleton, and disruption of this structure may be
involved in the pathogenesis of some muscle disorders (Law
et al., 1995; Miosge et al., 1999). Previous studies have im-
plicated the DGC in maintenance of the MTJ (Ridge et al.,
1994; Deconinck et al., 1997b), and our results suggest that
a main role of the DGC at this site may be to recruit  DB1.
Localization of  DB isoforms
In normal muscle,  DB1 is selectively associated with the
NMJ and MTJ, but when overexpressed transgenically it was
capable of association with extrasynaptic membrane. We
therefore wondered what factors account for the normally
distinct distributions of the two isoforms. Analysis of mdx
mice has shown that the extrasynaptic localization of  DB2
requires an intact DGC, so we considered the possibility that
the extrasynaptic localization of  DB2 seen in normal mice
results from the preferential binding of  DB2 over that of
 DB1 to the DGC. This competition might be accentuated
by the higher levels of  DB2 than  DB1 seen in normal
muscle (Fig. 1 B). However, analysis of the  DB
 / ,tgDB1/
DB2 double transgenics, in which  DB1 and  DB2 were
expressed at similar levels, showed that  DB1 was not dis-
lodged from its extrasynaptic position by  DB2. Thus the
extrasynaptic predominance of  DB2 in normal muscle is
not likely to be a result of competition between the isoforms.
Other reasons for the selective distribution of the two iso-
forms include the possibility that  DB1 might be selectively
transcribed from synaptic nuclei, analogous to the synaptic
expression of AChR subunits (for review see Sanes and Licht-
man, 2001). This is unlikely, however, because both isoforms
appear to be transcribed from the same promoter (Newey et
al., 2001a). Two remaining potential explanations are as fol-
lows: First, there may be posttranscriptional localization of
 DB1 mRNA either by synapse-specific stabilization of the
mRNA or by synapse-specific transport of the mRNA using
targeting information encoded in the 3  UTR (Newey et al.,
2001a). Second,  DB3 might play a role.  DB3 lacks the
syntrophin- and dystrophin-binding sites present in  DB1
and 2 (Nawrotzki et al., 1998) but is nonetheless associated
with the DGC (Yoshida et al., 2000). Thus, in normal mice
 DB3 may confine  DB1 to the NMJ by blocking its access
to extrasynaptic-binding sites. This interaction would not oc-
cur in  DB
 / ,tgDB1 muscle, which lacks  DB1–3.
 DB and the NMJ
 DB is a component of the molecular machinery that stabi-
lizes AChRs within the postsynaptic membrane. In  DB
mutants, the mobility of synaptic receptors is increased; as a
result, there is enhanced flux from the synapse to perijunc-
tional regions, which are sites of AChR internalization
(Sanes and Lichtman, 2001; Akaaboune et al., 2002). This
mechanism could explain, at least in part, the appearance of
the  DB
 /  postsynaptic membrane in which AChR turn-
over is abnormally high, density is low, and the distinction
between crests and troughs of junctional folds is blurred
(Grady et al., 2000; Akaaboune et al., 2002). Here, we show
that  DB1 is better able than  DB2 to rescue these synaptic
defects in  DB
 /  mice, indicating that its unique COOH
terminus is important for  DB’s synaptic function.
How might  DB act? One possibility is that  DB exerts
two distinct effects on the postsynaptic membrane, one me-
diated by common sequences and one by  DB1-specific se-
quences. Alternatively, common sequences might mediate
all synaptic effects, with  DB1-specific sequences serving to
enhance their efficacy. For example, even though regions
common to  DB1 and 2 bind both utrophin and  -syntro-
phin, there is some evidence that  DB1 associates more
tightly with both proteins than does  DB2 (Balasubrama-
nian et al., 1998; Peters et al., 1998) (Fig. 6). These differ-
ences are likely to be relevant because AChR density is de-
creased in the absence of utrophin (Deconinck et al.,
1997a, Grady et al., 1997a) and mice lacking  1-syntro-
phin have postsynaptic defects similar to those in  DB
 / 
mice (Adams et al., 2000). Thus, sequences in the unique
COOH terminus of  DB1 could enhance the ability ofT
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common sequences to bind utrophin and syntrophin,
thereby enhancing  DB1’s ability to stabilize the postsyn-
aptic membrane.
 DB phosphorylation and synaptic plasticity
Replacement of three tyrosine residues in  DB1’s unique
COOH-terminal domain by phenylalanine decreased its syn-
aptic efficacy. These residues are the major, if not the only
sites of tyrosine phosphorylation in  DB1 (Balasubramanian
et al., 1998) (Fig. 7 A). Our results, therefore, provide strong
evidence that  DB1 function is modulated by phosphoryla-
tion. Phosphorylation might alter the conformation of neigh-
boring sequences to affect their affinity for other proteins (as
suggested by modeling studies of Balasubramanian et al.,
1998) or may serve to recruit adaptor or signaling proteins as
occurs in numerous other phosphoproteins.
Our interest in  DB1 phosphorylation stems from the
growing realization that even though mature synapses are re-
markably stable, they are not inert. Instead, several of their
features, most notably the distribution and density of their
postsynaptic receptors, can change rapidly and dramatically
in response to altered input (Sheng and Lee, 2001). At the
NMJ, the t1/2 of AChRs increases, and their density begins
to decrease within 1 h after imposition of complete paralysis
(Akaaboune et al., 1999). AChR turnover and density are
similarly affected in  DB
 /  mice, suggesting that  DB is
part of the regulatory mechanism. However, actual loss of
 DB is unlikely to be a physiological mechanism for such
rapid activity-dependent alterations. On the other hand, al-
tered efficacy of  DB1 by changes in its phosphorylation
state could affect AChR mobility quickly, reversibly, and in
an activity-dependent fashion.
Several tyrosine kinases have been implicated in postsyn-
aptic structure: erbB and ephA kinases are concentrated in
the postsynaptic membrane; MuSK plays a critical role in
postsynaptic differentiation; src and fyn modulate AChR
stability in vitro; and trkB affects AChR distribution in vivo
(DeChiara et al., 1996; Gonzalez et al., 1999; Buonanno
and Fischbach, 2001; Lai et al., 2001; for review see Sanes
and Lichtman, 2001; Smith et al., 2001). It will be interest-
ing to learn whether  DB1 is a substrate for any of these ki-
nases and whether activators of the kinases (neuregulin for
erbBs, ephrinA for ephA, agrin for MuSK, and BDNF for
trkB) affect  DB1 phosphorylation. In addition, in view of
numerous reports implicating tyrosine kinases in central
synaptic plasticity and the presence of DGC components,
including  DB and  DB, at central synapses (Blake and
Kroger, 2000; Levi et al., 2002) it is intriguing to consider
the possibility that similar mechanisms act there.
Materials and methods
Generation of transgenic mice
To generate the  DB1 expression vector, two cDNA clones (16.1A and
14.1.2 [Enigk and Maimone, 1999]) were isolated from a BC3H1 mouse
muscle cDNA library and ligated. The 3  end of the cDNA, including the
stop codon and  125 bp of the 3  UTR, was generated by RT-PCR from
mouse muscle RNA. The entire coding region was then subcloned first into
the SalI/NotI sites of pBK-RSV (Stratagene) and then into a pEtCAT vector,
which contains 3.3 kb of regulatory sequences from the mouse muscle cre-
atine kinase gene, extending from  3,300 to  7 with respect to the tran-
scriptional start site (Jaynes et al., 1988) (a gift from S. Hauschka, Univer-
sity of Washington, Seattle, WA). In addition, the vector contains an SV40/
polyadenylation sequence. To generate the  DB2 expression vector, a full-
length clone was isolated from the BC3H1 library, subcloned into the
EcoRI site of pBluescript II SK( ) (Stratagene) and then into pEtCAT.
Linearized constructs were injected into C57BL6 oocytes at the Wash-
ington University Mouse Genetics Core. Four independent lines of mice
carrying the  DB1 construct (tgDB1) and six independent lines carrying
the  DB2 construct (tgDB2) were identified by PCR. Each line was bred
onto an  DB
 /  background (Grady et al., 1999).  DB
 / ,tgDB1 line was
also bred to mdx mice and to  DB
 / ,tgDB2 mice.
Histology
For bright field microscopy, muscles were frozen in liquid nitrogen–cooled
isopentane and cross sectioned in a cryostat at 8  m; sections were stained
with hematoxylin and eosin. For immunohistochemistry, sections from the
same muscles were stained with primary antibody diluted in PBS/1% BSA/
2% normal goat serum for 2 h and then rinsed with PBS. Sections were
then incubated 1 h with a mixture of fluorescein-conjugated goat anti–rab-
bit IgG (Alexa 488; Molecular Probes) and rBTX (Molecular Probes), rinsed
in PBS, and mounted using 0.1% p-phenylenediamine in glycerol/PBS. For
en face views, sternomastoid muscles were fixed in 1% PFA in PBS for 20
min, cryoprotected in sucrose, frozen, and sectioned en face at 40  m.
Rabbit polyclonal antibodies to  DB1 ( DB638),  DB2, and  1-syntro-
phin (SYN17) were gifts from Stanley Froehner, University of Washington
(Peters et al., 1997b). Rabbit polyclonal antibodies that recognize all forms
of  DB (called pan- DB here) were generated using a recombinant frag-
ment of  DB and affinity purified using the immunogen (Grady et al.,
1997a). Rabbit polyclonal antibody to nNOS was purchased from Immu-
nostar Inc. (no. 24287). Illustrations were prepared in Adobe Photoshop
®.
For ultrastructural studies, tibialis anterior muscles were fixed in 4% glu-
taraldehyde/4% PFA in PBS, washed, refixed in 1% OsO4, dehydrated, and
embedded in resin. Thin sections were stained with lead citrate and uranyl
acetate. Sections were systematically scanned in the electron microscope,
and all MTJs encountered were measured from the micrographs. Muscles
from two to four animals were analyzed per genotype.
Immunoblotting
For immunoblots, sternomastoid muscle was homogenized and sonicated
in extraction buffer (PBS, 5 mM EDTA, 1% SDS, and protease inhibitors
[CompleteMini; Roche]). Protein concentration of whole muscle extract
was determined by a BCA protein assay (Pierce Chemical Co.). Equal
amounts of protein (50  g) were resolved on 7.5% SDS–polyacrylamide
gels and incubated with monoclonal antibody to  DB (D62320; Transduc-
tion Laboratories). This antibody was detected with goat anti–mouse IgG1
peroxidase-conjugated secondary antibody (Roche) using ECL (NEN).
Quantitative fluorescence microscopy and in vivo imaging
AChR density at NMJs was calculated using the quantitative fluorescence
imaging technique described by Akaaboune et al. (1999, 2002). Briefly,
mice were anesthetized, and the exposed sternomastoid muscle was satu-
rated with rBTX (5  g/ml) for 60 min, and superficial NMJs were viewed
with a fluorescence microscope. The fluorescence intensity at synapses was
compared with that of a nonbleaching fluorescent standard viewed concur-
rently. To study loss rate of AChRs, a nonblocking dose of rBTX (0.1  g/ml)
was applied to the sternomastoid for 2–5 min and 1 d later, after unbound
toxin had cleared, individual synapses were imaged. Total fluorescence in-
tensity at the first view was expressed as 100%. Mice were then reexamined
3 d later, and total fluorescence intensity of the previously identified junc-
tions was measured (Akaaboune et al., 1999). The use of a nonblocking
dose ensured that the turnover rate was not affected by paralysis.
Comparison of transgenic lines
Of the four  DB1 transgenic lines examined on a  DB
 /  background, two
(lines 12 and 14) expressed detectable  DB1. More than 95% of muscle fi-
bers expressed  DB in line 12 but only 50–70% in line 14. However, both
lines were similar in that expression of the transgene prevented dystrophy
in transgene-positive fibers and led to a more normal synaptic structure
than observed in  DB
 / ,tgDB2 transgenic lines. Of the six  DB2 lines ex-
amined, expression was detected in three (lines 11A, 11B, and 28). Results
from  DB
 / ,tgDB2 lines 11B and 28 were similar in all respects tested (mus-
cle and synaptic structure and AChR turnover). Levels of transgene expression
were lower in line 11A, and only  70% of muscle fibers in  DB
 / ,tgDB2
line 11A mice were transgene positive. No central nuclei occurred in these
transgene-positive fibers, indicating rescue of the dystrophic phenotype,
but rescue of the synaptic phenotype was significantly less in this line than
in any of the other lines tested. In summary, all five transgenic lines testedT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 Dystrobrevin isoforms | Grady et al. 751
exhibited rescue of the dystrophic phenotype, and both tgDB1 lines res-
cued synaptic defects more effectively than any of the tgDB2 lines. Based
on these results, we studied  DB
 / ,tgDB1 line 12 and  DB
 / ,tgDB2 line
28 in greatest detail.
In vitro and in vivo transfection
Expression vector GFP-DB1 was constructed by cloning the  DB1 cDNA
described above into a pEGFP-C1 plasmid (CLONTECH Laboratories,
Inc.), generating a fusion protein with GFP attached to the NH2 terminus of
 DB1. To create GFP-DB1-P3
 , PCR-directed mutagenesis was used to
change three terminal tyrosine residues (aa 698, 706, and 723) to phenyl-
alanine. These residues correspond to aa 685, 693 and 710, which were
shown to be major if not sole sites of tyrosine phosphorylation in Torpedo
 DB (Balasubramanian et al., 1998).
The  DB1 constructs were transfected into HEK293 cells using Lipo-
fectamine Plus transfection reagent (Invitrogen) and 4  g of DNA per 10-
cm dish. Cells were harvested 48 h after transfection. Immediately before
collection, cells were subjected to pervanadate stimulation to inhibit tyro-
sine phosphatases as described by Balasubramanian et al. (1998). Soluble
fractions were collected and immunopurified by incubating with GFP spe-
cific antibodies (A-11120; Molecular Probes) for 1 h at 4 C, and then with
protein G sepharose beads (Amersham Biosciences) for 3 h more. Beads
were precipitated, washed, resuspended in 1  sample buffer, boiled for 4
min, and subjected to immunoblotting (see above).  DB was detected us-
ing an mAb (D62320, Transduction Labs), and phosphotyrosine was de-
tected using PY20 antibody (610000, Transduction Labs).
For in vivo electroporation, DNA was dissolved into normal saline
(0.9% NaCl) at a concentration of 2  g/ l. Mice were anesthetized, and
their tibialis anterior muscles were injected transcutaneously with 25  l of
a 4 U/ L bovine hyaluronidase/saline solution (Sigma-Aldrich) as recom-
mended by McMahon et al. (2001). 2 h later, the mice were reanesthe-
tized, the tibialis was exposed, injected with 25  l of DNA (50  g), and
electroporated (Aihara and Miyazaki, 1998). Electroporation was per-
formed with a pair of 0.2-mm diameter stainless steel needle electrodes
(Genetronics) held 4 mm apart and inserted on either side of the injection
site parallel to the muscle fibers. Ten 80 V pulses, each 20 ms in duration,
were delivered at a frequency of 1 Hz, giving a field strength of  200 V/cm
(BTX electroporator). Muscles were dissected 10–14 d after injection and
fixed for 20 min in 1% PFA. Fiber bundles exhibiting GFP fluorescence
were isolated under a fluorescence dissecting microscope, stained with
rBTX and viewed by both light (Carl Zeiss MicroImaging, Inc.) and confo-
cal (Olympus) microscopy.
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